AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for... | June 12, 2023

Related Keywords

China ,Nebraska ,United States ,Ohio ,Chicago ,Illinois ,Netherlands ,South Africa ,Argentina ,University Of Nebraska Medical Center ,American ,Canton ,South African ,Thomask Equels ,Kelsey Klute ,Rintatolimod Ampligen ,Erasmus Medical Center ,Roswell Park Comprehensive Cancer Center ,Immunotech Inc ,Facebook ,Gabrail Cancer Research Center ,Early Access Program ,Linkedin ,Netherlands At Erasmus Medical Center ,Company On Twitter ,University Of Nebraska ,Pancreas Club Meeting ,Trademark Office ,Center Named Patient Program ,Executive Officer Thomas ,Locally Advanced Pancreatic Cancer ,Nebraska Medical Center ,Gabrail Cancer ,Research Center ,Medical Director ,Pancreatic Diseases Specialty Clinic ,Nebraska Medicine ,Early Stage Triple Negative Breast Cancer ,Roswell Park Comprehensive Cancer ,Annual Meeting ,Analysis Demonstrating Potential ,Stable Pancreatic Cancer ,Rintatolimod Treatment ,Enhances Numbers ,Peripheralb Cells ,Longer Survival ,Locally Advanced ,Metastasized Pancreatic Cancer Pre Treated ,Single Center Named Patient Program ,Potential Therapy Against Ebola Virus Disease ,South African Patent ,Methods Useful ,Ebola Virus Infection ,Erasmus Medical ,